Clinical Trials Directory

Trials / Unknown

UnknownNCT00482716

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
St. Bartholomew's Hospital · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether epoetin alfa or epoetin beta are more effective when given with or without iron infusion in treating anemia in patients with cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare how well they work with or without iron infusion in treating anemia in patients with cancer.

Detailed description

OBJECTIVES: * Compare the efficacy of recombinant epoetin alfa or epoetin beta with vs without parenteral iron in anemic, iron-replete patients with nonmyeloid malignancies. OUTLINE: This is a randomized, controlled, open-label, prospective study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive recombinant erythropoietic stimulatory activity (ESA) therapy comprising epoetin alfa or epoetin beta subcutaneously (SC) on day 1. * Arm II: Patients receive ESA therapy as in arm I and parenteral iron (i.e., low molecular weight iron dextran complex IV over 5-10 minutes or iron sucrose injection IV over 10-30 minutes) on day 1. In both arms, treatment repeats weekly for up to 10 weeks or until hemoglobin reaches 13 g/dL, whichever comes first.

Conditions

Interventions

TypeNameDescription
BIOLOGICALepoetin alfa
BIOLOGICALepoetin beta
DIETARY_SUPPLEMENTiron dextran complex
DIETARY_SUPPLEMENTiron sucrose injection

Timeline

Start date
2007-01-01
First posted
2007-06-05
Last updated
2014-01-10

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00482716. Inclusion in this directory is not an endorsement.